Core Viewpoint - The company, Kanghua Biological (300841.SZ), has announced the termination of its collaboration on the development of mRNA vaccines for tuberculosis, rabies, and shingles with Xinran Bochuang, citing strategic business considerations. This decision is not expected to significantly impact the company's normal operations [1]. Group 1 - The company has signed a supplementary agreement to terminate the mRNA vaccine development projects [1] - The decision to end the collaboration was made after considering the overall business development plan of the company [1] - The company has established its own R&D team and completed the transfer of collaborative research results [1]